This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Popoli, P. Articles by Reggio, R. Search for Related Content PubMed PubMed Citation Articles by Popoli, P. Articles by Reggio, R.

NEUROLOGY 2003;61:S69-S71
© 2003 American Academy of Neurology

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Modulation of glutamate release and excitotoxicity by adenosine A_2A receptors

P. Popoli, MD, C. Frank, MD, M.T. Tebano, MD, R.L. Potenza, BSc, A. Pintor, BSc, M.R. Domenici, BSc, V. Nazzicone, A. Pèzzola and R. Reggio

From the Department of Pharmacology, Istituto Superiore di Sanità, Rome, Italy.

Address correspondence and reprint requests to Dr. Patrizia Popoli, Department of Pharmacology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy; e-mail: patrizia.popoli{at}iss.it

Because an increased glutamate outflow is thought to play a crucial role in triggering excitotoxic neuronal death, drugs able to regulate glutamate release could be effective for the management of neurodegenerative diseases. In this article, the authors discuss the hypothesis that adenosine A_2A receptor antagonists (A_2A antagonists) may belong to the aforementioned category. In rats bilaterally lesioned with the excitotoxin quinolinic acid (QA) in the striatum, the A_2A antagonist SCH 58261 significantly reduced the motor, EEG, and neuropathologic changes induced by the lesion. Such effects of SCH 58261 occurred only at low doses and were paralleled by an inhibition of QA-stimulated glutamate release. The role played by A_2A antagonists in the regulation of glutamate outflow was also confirmed by preliminary results obtained in the model of paired-pulse stimulation in corticostriatal slices. Conversely, based on data obtained in cultured striatal neurons, A_2A antagonists appear unable to directly inhibit NMDA effects. In conclusion, A_2A antagonists show clear neuroprotective effects in models of brain injury, although their actual therapeutic potential needs to be confirmed in a wider range of doses and in models of neurodegenerative diseases in which presynaptic and postsynaptic effects play different relative roles.

This article has been cited by other articles:

				R. A. Hodgson, R. Bertorelli, G. B. Varty, J. E. Lachowicz, A. Forlani, S. Fredduzzi, M. E. Cohen-Williams, G. A. Higgins, F. Impagnatiello, E. Nicolussi, et al. Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 294 - 303. [Abstract] [Full Text] [PDF]

				H. Shen, G.-J. Chen, B. K. Harvey, P. C. Bickford, and Y. Wang Inosine Reduces Ischemic Brain Injury in Rats Stroke, March 1, 2005; 36(3): 654 - 659. [Abstract] [Full Text] [PDF]